Augurix Diagnostics SA is a startup that was founded in 2007. It transferred its activities to BioArk at Monthey on 1st February 2010. The company developed a diagnostic test for coeliac disease, also known as gluten intolerance, and launched it onto the market. This product is based on technology patented by Augurix and enables several reliable, easily-interpreted measurements to be taken in one simple, rapid operation.

The technology platform patented by Augurix provides a simple means of screening blood, serum, plasma or saliva within 10 minutes, without needing to use a laboratory.

Augurix carries out its research and development activities and its quality control at Monthey. Part of the manufacturing takes place in Great Britain, with packaging and assembly being undertaken by a subsidiary company in the Czech Republic. The marketing approach differs from country to country, but is largely based on a network of distributors rather than direct selling.


Support from The Ark Foundation

Since 2010, Augurix has been based at the BioArk premises in Monthey, where it benefits from a range of coaching and other services to help it become established. For over a year, the company has also been receiving support for the development of its second product via the Innovation service of The Ark Foundation.

Date founded: 2007
Director: Gino Borrelli
Address: Route de l’Ile-au-Bois 1a, 1870 Monthey, Switzerland
Telephone: +41 848 253 422
Website: www.augurix.com
Email: info [at] augurix.com
Number of employees: 7
Fondation The Ark - Route du Rawyl 47 - 1950 Sion - Suisse | Intranet The Ark